Previous Article | Next Article 
Infection and Immunity, February 1999, p. 527-538, Vol. 67, No. 2
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Serum Antitoxin Antibodies Mediate Systemic and
Mucosal Protection from Clostridium difficile
Disease in Hamsters
Paul J.
Giannasca,*
Zhen-xi
Zhang,
Wen-de
Lei,
James A.
Boden,
Mary Ann
Giel,
Thomas P.
Monath, and
William D.
Thomas Jr.
OraVax, Inc., Cambridge, Massachusetts 02139
Received 21 August 1998/Returned for modification 25 September
1998/Accepted 4 November 1998
Clostridium difficile is the bacterial pathogen
identified as the cause of pseudomembranous colitis and is principally
responsible for nosocomial antibiotic-associated diarrhea and colitis.
The pathologic findings associated with this infection are believed to
be caused by two large (~300-kDa) exotoxins, toxins A and B. Because
of the mucosal nature of this infection, vaccination strategies aimed
at providing prophylactic or therapeutic immune protection have
included immunization by mucosal routes. Using the hamster model of
C. difficile infection, we examined the protective efficacy of inactivated toxin (toxoid) vaccine formulations prepared as either
culture filtrate or partially purified toxoid. We compared combination
parenteral and mucosal vaccination regimens involving intranasal,
intragastric, or rectal routes of immunization and found that rectal
immunization in conjunction with intramuscular (i.m.) vaccination
provided full protection of hamsters from death and diarrhea while the
other mucosal routes did not. Protection was associated with high
levels of toxin-neutralizing antibodies in serum. The requirement for
adjuvants for protection was assessed by using sequential i.m. and
rectal or i.m. vaccination regimens. Unexpectedly, i.m. immunization
without adjuvant conferred the highest protection from death and
diarrhea; this regimen elicited the highest serum anti-toxin B titers
as well as toxin B neutralizing titers. Passive transfer of mouse
antitoxin antibodies protected hamsters in a dose-dependent manner,
demonstrating the principal role of circulating antitoxin antibodies in
immunity from this toxin-mediated mucosal disease. These results
suggest that prophylactic parenteral vaccination or intravenous
immunotherapy could provide protection from C. difficile
disease in humans.
*
Corresponding author. Mailing address: OraVax, Inc., 38 Sidney St., Cambridge, MA 02139. Phone: (617) 494-1339. Fax: (617) 494-0927. E-mail: pgiannas{at}oravax.com.
Infection and Immunity, February 1999, p. 527-538, Vol. 67, No. 2
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Goulding, D., Thompson, H., Emerson, J., Fairweather, N. F., Dougan, G., Douce, G. R.
(2009). Distinctive Profiles of Infection and Pathology in Hamsters Infected with Clostridium difficile Strains 630 and B1. Infect. Immun.
77: 5478-5485
[Abstract]
[Full Text]
-
Ghose, C., Kalsy, A., Sheikh, A., Rollenhagen, J., John, M., Young, J., Rollins, S. M., Qadri, F., Calderwood, S. B., Kelly, C. P., Ryan, E. T.
(2007). Transcutaneous Immunization with Clostridium difficile Toxoid A Induces Systemic and Mucosal Immune Responses and Toxin A-Neutralizing Antibodies in Mice. Infect. Immun.
75: 2826-2832
[Abstract]
[Full Text]
-
Babcock, G. J., Broering, T. J., Hernandez, H. J., Mandell, R. B., Donahue, K., Boatright, N., Stack, A. M., Lowy, I., Graziano, R., Molrine, D., Ambrosino, D. M., Thomas, W. D. Jr.
(2006). Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile-Induced Mortality in Hamsters. Infect. Immun.
74: 6339-6347
[Abstract]
[Full Text]
-
Castagliuolo, I., Sardina, M., Brun, P., DeRos, C., Mastrotto, C., Lovato, L., Palu, G.
(2004). Clostridium difficile Toxin A Carboxyl-Terminus Peptide Lacking ADP-Ribosyltransferase Activity Acts as a Mucosal Adjuvant. Infect. Immun.
72: 2827-2836
[Abstract]
[Full Text]
-
Mylonakis, E., Ryan, E. T., Calderwood, S. B.
(2001). Clostridium difficile-Associated Diarrhea: A Review. Arch Intern Med
161: 525-533
[Abstract]
[Full Text]
-
Kotloff, K. L., Wasserman, S. S., Losonsky, G. A., Thomas, W. Jr., Nichols, R., Edelman, R., Bridwell, M., Monath, T. P.
(2001). Safety and Immunogenicity of Increasing Doses of a Clostridium difficile Toxoid Vaccine Administered to Healthy Adults. Infect. Immun.
69: 988-995
[Abstract]
[Full Text]
-
Pavliakova, D., Moncrief, J. S., Lyerly, D. M., Schiffman, G., Bryla, D. A., Robbins, J. B., Schneerson, R.
(2000). Clostridium difficile Recombinant Toxin A Repeating Units as a Carrier Protein for Conjugate Vaccines: Studies of Pneumococcal Type 14, Escherichia coli K1, and Shigella flexneri Type 2a Polysaccharides in Mice. Infect. Immun.
68: 2161-2166
[Abstract]
[Full Text]
-
Stubbe, H., Berdoz, J., Kraehenbuhl, J.-P., Corthesy, B.
(2000). Polymeric IgA Is Superior to Monomeric IgA and IgG Carrying the Same Variable Domain in Preventing Clostridium difficile Toxin A Damaging of T84 Monolayers. J. Immunol.
164: 1952-1960
[Abstract]
[Full Text]
-
Ward, S. J., Douce, G., Dougan, G., Wren, B. W.
(1999). Local and Systemic Neutralizing Antibody Responses Induced by Intranasal Immunization with the Nontoxic Binding Domain of Toxin A from Clostridium difficile. Infect. Immun.
67: 5124-5132
[Abstract]
[Full Text]